Camurus said the FDA has accepted for review the resubmitted NDA for CAM2029 (octreotide), setting the PDUFA target action date for 18 Dec 2026. The acceptance is a key regulatory milestone that reduces near-term uncertainty versus non-acceptance, supporting modest positive sentiment for the program’s timeline.
Camurus said the FDA has accepted for review the resubmitted NDA for CAM2029 (octreotide), setting the PDUFA target action date for 18 Dec 2026. The acceptance is a key regulatory milestone that reduces near-term uncertainty versus non-acceptance, supporting modest positive sentiment for the program’s timeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
